Építés alatt – nem éles oldal
Belépés
Befejeződött3. fázis

A Phase 3 Study to Assess the Immune Response and Safety of rMenB+OMV NZ in Primed Healthy Participants (10 to 20 Years Old)

A legfontosabb adatok

Ki végzi
GlaxoSmithKline
Hol
Egyesült Királyság, Finnország, Olaszország és Spanyolország17 helyszín, 4 országbanVálassz országot a helyszínekhez
Állapot
Befejeződött
Fázis
3. fázis
Résztvevők
312 fő vett részt
Kezdés
2025. júl. 7.
Befejezés
2025. dec. 15.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
A vizsgált kezelések
  • rMenB+OMV NZ vaccine
A regiszteradat frissítve
2026. november 6.

Ki vehet részt

Életkor
10 év – 20 év
Nem
Nők és férfiak
Egészséges önkéntesek
Részt vehetnek

A regiszter feltételei, szó szerint

Mind a 26 feltétel megnézéseKevesebb

Ki vehet részt

  • Participants were eligible to be included in the study only if all of the following criteria applied:
  • For primed group only:
  • Participated who were primed with rMenB + OMV NZ in only either 3+1 or 2+1 schedule during the first 2 years of life as confirmed by electronic or paper vaccination record; OR; For naïve group only:
  • Electronic or paper vaccination record confirmed participant who has never received any group B meningococcal vaccine and is recruited in the same country as primed participants; For all participants:
  • Participants and/or participants' parent(s)/ legally acceptable representative(s) (LAR[s]), who, in the opinion of the investigator, can and will comply with the requirements of the protocol
  • Written or witnessed/thumb printed informed consent obtained from the participant / parent(s)/LAR(s) of the participant prior to performance of any study-specific procedure
  • Written informed assent obtained from the participant (if applicable) along with informed consent from the participant's parent(s)/LAR(s) prior to performing any study specific procedure; Note: For age 10-16 years, parents or LAR to give consent along with participants, based on country regulations for participants and for >16/18 to 20 years, participants give consent independent of parents/LARs, or as per local country regulations
  • A male or female between, and including, 10 and 20 years of age at the time of the first study intervention administration
  • Female participants of non-childbearing potential may be enrolled in the study. Non-childbearing potential is defined as pre-menarche, hysterectomy, bilateral ovariectomy
  • Female participants of childbearing potential may be enrolled in the study, if the participant:; has practiced adequate contraception for 1 month prior to study intervention administration, and; has a negative pregnancy test on the day of study intervention administration, and; has agreed to continue adequate contraception during the entire study treatment period

Ki nem vehet részt

  • Current or previous, confirmed or suspected disease caused by N. meningitidis
  • Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the participant due to participation in the study; Prior/Concomitant therapy
  • Use of any investigational or non-registered product (drug, vaccine or medical device) other than the study intervention during the period beginning 30 days before the first dose of study intervention (Day -29 to Day 1), or their planned use during the study period
  • Chronic administration of immune-modifying drugs (defined as more than 14 consecutive days in total) and/or planned use of long-acting immune-modifying treatments at any time up to the end of the study; Within 90 days prior to study intervention administration: for corticosteroids, this will mean prednisone equivalent >=20 milligram (mg)/day for adult participants or >=0.5 mg/kg/day with maximum of 20 mg/day for pediatric participants. Inhaled and topical steroids are allowed; Within 90 days prior to study intervention administration: long-acting immune-modifying drugs including among others immunotherapy (e.g., TNF-inhibitors), monoclonal antibodies, antitumoral medication
  • Administration of immunoglobulins and/or any blood products or plasma derivatives within 180 days prior to study intervention administration and/or planned use at any time up to the end of the study; For primed group only:
  • Participants who received additional dose(s) of group B meningococcal vaccine other than 2+1 or 3+1 schedule prior to study intervention administration; Prior/Concurrent clinical study experience
  • Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational intervention (drug/vaccine/invasive medical device); Other exclusion criteria
  • Medical conditions
  • History of any reaction or hypersensitivity likely to be exacerbated by any component of the study intervention
  • Medical conditions representing a contraindication to intramuscular vaccination and blood draws
  • Known exposure to an individual with laboratory confirmed N. meningitidis infection, within 60 days prior to enrollment
  • Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required)
  • Participants were excluded from the study if any of the following criteria applied:
  • Pregnant or lactating female participant
  • Any study personnel or their immediate dependents, family, or household member
  • Child in care

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

4 országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

The main purpose of this study was to evaluate the immune response and safety of a booster dose of the meningococcal group B vaccine, rMenB+OMV NZ (also known as Bexsero), in adolescents and young adults aged 10 to 20 years. This study focused on individuals who were first vaccinated with rMenB+OMV NZ as infants. The primary hypothesis was that a booster dose of the vaccine would elicit a stronger immune response in these primed individuals compared to those who had never received any group B meningococcal vaccine, referred to as 'naïve' participants.

A vizsgálat 2 csoportja

  • Primed groupA vizsgált kezelés

    Participants who were primed with rMenB+OMV NZ vaccine in a 3 (2+1) doses or 4 (3+1) doses vaccination schedule during the first 2 years of life, received 1 dose of rMenB+OMV NZ vaccine at Day 1.

    Kezelés: rMenB+OMV NZ vaccine

  • Naïve groupMár használt kezelés, összehasonlításként

    Participants who never received any group B meningococcal vaccine previously, received 2 doses of rMenB+OMV NZ vaccine, one at Day 1 and one at Day 31.

    Kezelés: rMenB+OMV NZ vaccine

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Phase 3b, Open-Label, Multi-Center Study to Assess the Immune Response and Safety of the Meningococcal Group B Vaccine rMenB+OMV NZ When Administered to Healthy Participants Aged 10 to 20 Years Old, Who Were Primed During the First 2 Years of Life
A regiszteradat frissítve
2026. november 6.